Basic research for the development of multi-peptide cocktail vaccines for cancer
| Project/Area Number |
23501292
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor immunology
|
|---|
| Research Institution | Kurume University |
|---|
Principal Investigator |
YAMADA Akira 久留米大学, 先端癌治療研究センター, 教授 (50158177)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | ワクチン療法 / がんワクチン / 免疫療法 / がん / ペプチドワクチン / CTL / ペプチド / 混合ワクチン / 抗体 |
|---|
| Research Abstract |
Personalized peptide vaccine therapy must overcome several hurdles before being used as a general treatment for cancer. To this end, non-personalized multi-peptide cocktail vaccines that exhibit similar clinical effects without requiring time-consuming laboratory tests will be needed. In the present study, we have developed two new cocktail vaccines consisting of 20 peptides (KRM-20) and 10 peptides (KRM-10) for the treatment of prostate cancer and gastrointestinal cancers, respectively, by selecting the reactivity levels of their plasma IgG antibodies and cytotoxic T-lymphocyte-inducing activities. In addition, immunological analyses of blood samples of clinical trials suggested the immunological minimum effective doses.
|
Report
(4 results)
Research Products
(94 results)
-
-
-
-
-
[Journal Article] Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients.2014
Author(s)
Kawano K, Tsuda N, Matsueda S, Sasada T, Watanabe N, Ushijima K, Yamaguchi T, Yokomine M, Itoh K, Yamada A, Kamura T.
-
Journal Title
Immunopharmacol Immunotoxicol
Volume: in press
Related Report
Peer Reviewed
-
-
-
-
[Journal Article] Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: a new biomarker for overall survival of patients with malignant diseases.2013
Author(s)
Matsueda S, Komatsu N, Kusumoto K, Koga S, Yamada A, Kuromatsu R, Yamada S, Seki R, Yutani S, Shichijo S, Mine T, Fukuda T, Okamura T, Okuda S, Sata M, Honda J, Kaji M, Itoh K, Sasada T.
-
Journal Title
Dev Comp Immunol.
Volume: 41(1)
Issue: 1
Pages: 68-76
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
[Journal Article] Personalized peptide vaccination in patients with refractory non-small cell lung cancer.2012
Author(s)
Yoshiyama K, Terazaki Y, Satoko Matsueda S, Shichijo S, Noguchi M, Yamada A, Mine T, Ioji T, Itoh K, Shirouzu K, Sasada T and Takamori S.
-
Journal Title
Int J Oncol
Volume: 40
Pages: 1492-1500
DOI
Related Report
Peer Reviewed
-
[Journal Article] In vitro induction of specific CD8(+) T lymphocytes by tumorassociated antigenic peptides in patients with oral squamous cell carcinoma2012
Author(s)
Toyoshima, T., Kumamaru, W., Hayashida, J.-N., Moriyama, M., Kitamura, R., Tanaka, H., Yamada, A., Itoh, K., and Nakamura, S.
-
Journal Title
Cancer Lett
Volume: 322
Issue: 1
Pages: 86-91
DOI
Related Report
Peer Reviewed
-
-
-
[Journal Article] Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status, and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis.2012
Author(s)
Yoshitomi M, Yutani S, Matsueda S, Ioji T, Komatsu N, Shichijo S, Yamada A, Itoh K, Sasada T, Kinoshita H.
-
Journal Title
Exp Ther Med
Volume: 3
Pages: 463-469
Related Report
Peer Reviewed
-
[Journal Article] Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status, and pre-existing antigen -specific immunity as possible biomarkers for patient prognosis.2012
Author(s)
Yoshitomi M, Yutani S, Matsueda S, Ioji T, Komatsu N, Shichijo S, Yamada A, Itoh K, Sasada T, Kinoshita H.
-
Journal Title
Exp Ther Med
Volume: 3
Pages: 463-469
Related Report
Peer Reviewed
-
[Journal Article] Personalized peptide vaccination in patients with refractory non-small cell lung cancer.2012
Author(s)
Yoshiyama K, Terazaki Y, Matsueda S, Shichijo S, Noguchi M, Yamada A, Takashi M, Tetsuya I, Kyogo I, Kazuo S, Tetsuro S, Shinzo T.
-
Journal Title
Int J Oncol
Volume: 40
Pages: 1492-1500
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
[Journal Article] Phase-I clinical study of a personalized peptide vaccination available for six different HLA (HLA-A2, -A3, -A11, -A24, -A31, and -A33)-positive patients with advanced cancer.2011
Author(s)
Yamada A, Noguchi M, Komatsu N, Suekane S, Yutani S, Moriya F, Mine T, Momozono K, Kawano K, Itoh K.
-
Journal Title
Exp Ther Med
Volume: 2
Pages: 109-117
Related Report
Peer Reviewed
-
[Journal Article] A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin.2011
Author(s)
Matsumoto K, Noguchi M, Satoh T, Tabata K, Fujita T, Iwamura M, Yamada A, Komatsu N, Baba S, Itoh K.
-
Journal Title
BJU Int
Volume: 108
Issue: 6
Pages: 831-838
DOI
Related Report
Peer Reviewed
-
[Journal Article] A Phase I Trial of Personalized Peptide Vaccine for HLA-A24 Patients with Recurrent or Progressive Glioblastoma Multiforme.2011
Author(s)
Terasaki M,Shibui S, Narita Y, Fujimaki T, Aoki T, Kajiwara K, Sawamura Y, Kurisu K, Mineta T, Yamada A, Itoh K.
-
Journal Title
J Clin Oncol
Volume: 29
Pages: 337-344
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
